The story of Viagra, and its parent company copyright, presents a complex case study for investors. Initially a blockbuster drug, yielding billions in revenue , its intellectual property lapse created a wave of knock-off medications, significantly eroding its dominance. While certain pharmaceutical companies may seek to capitalize on similar condit